Tuberculosis treatment intervention trials in Africa: A cross-sectional bibliographic study and spatial analysis

• Published in: PloS one Vol. 16; no. 3; p. e0248621
• Main Authors: Hohlfeld, Ameer S J, Mathebula, Lindi, Pienaar, Elizabeth D, Abrams, Amber, Lutje, Vittoria, Ndwandwe, Duduzile, Kredo, Tamara
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.03.2021; Public Library of Science (PLoS)
• Subjects: Care and treatment; Medicine and Health Sciences; Patient outcomes; People and Places; Research and Analysis Methods; Tuberculosis; Africa
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0248621

Mycobacterium Tuberculosis (TB) poses a substantial burden in sub-Saharan Africa and is the leading cause of death amongst infectious diseases. Randomised controlled trials (RCTs) are regarded as the gold standard for evaluating the effectiveness of interventions. We aimed to describe published TB treatment trials conducted in Africa. This is a cross-sectional study of published TB trials conducted in at least one African country. In November 2019, we searched three databases using the validated Africa search filter and Cochrane's sensitive trial string. Published RCTs conducted in at least one African country were included for analysis. Records were screened for eligibility. Co-reviewers assisted with duplicate data extraction. Extracted data included: the country where studies were conducted, publication dates, ethics statement, trial registration number, participant's age range. We used Cochrane's Risk of Bias criteria to assess methodological quality. We identified 10,495 records; 175 trials were eligible for inclusion. RCTs were published between 1952 and 2019. The median sample size was 206 participants (interquartile range: 73-657). Most trials were conducted in South Africa (n = 83) and were drug therapy trials (n = 130). First authors were from 30 countries globally. South Africa had the most first authors (n = 55); followed by the United States of America (USA) (n = 28) and Great Britain (n = 14) with fewer other African countries contributing to the first author tally. Children under 13 years of age eligible to participate in the trials made up 17/175 trials (9.71%). International governments (n = 29) were the most prevalent funders. Ninety-four trials provided CONSORT flow diagrams. Methodological quality such as allocation concealment and blinding were poorly reported or unclear in most trials. By mapping African TB trials, we were able to identify potential research gaps. Many of the global north's researchers were found to be the lead authors in these African trials. Few trials tested behavioural interventions compared to drugs, and far fewer tested interventions on children compared to adults to improve TB outcomes. Lastly, funders and researchers should ensure better methodological quality reporting of trials.